Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence |
| |
Authors: | Rosenson Robert S Brown Alan S |
| |
Institution: | Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA. r-rosenson@nothwestern.edu |
| |
Abstract: | PURPOSE OF REVIEW: Review the cellular mechanisms and clinical evidence for the use of statins in patients with unstable coronary syndromes. RECENT FINDINGS: Clinical trials of statin therapy in acute coronary syndromes demonstrate a rapid improvement in endothelial function, improved perfusion to ischemic myocardium, and an early reduction in cardiovascular events. The early benefit of statin therapy is related to a combination of molecular mechanisms that involve the oxidized LDL receptor (LOX-1), endothelial localized nitric oxide synthase, inflammatory cytokines, interstitial collagenases, and tissue factor expression. In human atheroma, 3 months' use of statin (pravastatin) therapy reduced the content of oxidized LDL, inflammatory cells (macrophage, T cells) infiltrates, and improved plaque stability by increasing the collagen content of the fibrous cap. SUMMARY: The antiatherothrombotic effects of statin therapy appear to have important clinical relevance to patients with impaired myocardial perfusion and acute coronary syndrome. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|